Sonnet biotherapeutics announces 1-for-22 reverse stock split

Princeton, nj / accesswire / august 31, 2023 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it will effect a 1-for-22 reverse stock split of its outstanding common stock. this will be effective for trading purposes as of the commencement of trading on friday, september 1, 2023.
SONN Ratings Summary
SONN Quant Ranking